<DOC>
	<DOCNO>NCT02598453</DOCNO>
	<brief_summary>The purpose study evaluate treatment adherence different regimen ibandronate postmenopausal woman osteoporosis osteopenia intolerant daily weekly alendronate risedronate therapy due gastrointestinal ( GI ) side effect . The anticipated time study treatment 12 month , target sample size 517 individual .</brief_summary>
	<brief_title>PRIOR Study - A Study Ibandronate ( Boniva ) Postmenopausal Women With Osteoporosis Osteopenia</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Women postmenopausal osteoporosis osteopenia Discontinuation daily /or weekly alendronate risedronate therapy GI intolerance ( eg , heartburn , acid reflux , stomach upset ) Inability stand sit upright 60 minute Inability swallow tablet whole Hypersensitivity component Boniva Malignant disease diagnose within previous 10 year ( except resect basal cell cancer ) ; contraindication calcium vitamin D therapy Patients fulfill minimum 3 month washout therapy previous bisphosphonate therapy</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>